Insights - Page 48 of 107 - LucidQuest Ventures

Hematology Video Recap—November 3, 2025

November 3, 2025gsk,Multiple Myeloma,Hemophilia A,BioPharma and Tech News,Novo Nordisk,Heidelberg Pharma,Acute Myeloid Leukemia,Hematology News,Lantern Pharma,syndax pharmaceuticals,moleculin biotech,geneventiv therapeuticsbiomarin pharmaceutical,non-hodgkin lymphoma

In this biweekly video we cover FDA and MHRA decisions across multiple…

by LucidQuest

Oncology Today—November 3, 2025

November 3, 2025merck,BioPharma and Tech News,Pancreatic cancer,Keytruda,pembrolizumab,iopofosine I-131,Oncology News,Cellectar Biosciences,Non-small cell lung cancerPediatric high-grade glioma,HER2-low breast cancer

This week’s oncology news delivers the latest updates, developments, and…

by LucidQuest

Hematology Today—November 3, 2025

November 3, 2025gene therapy,Sickle Cell Disease,Hemophilia A,BioPharma and Tech News,AML,DLBCL,antibody drug conjugate,Hematology News,Lantern Pharma,Large B-cell lymphomaMyeloproliferative neoplasms,Glofitamab

Catch the latest hematology news, featuring industry updates, clinical…

by LucidQuest

Lucid Diligence Brief: Thermo Fisher to acquire Clario

November 3, 2025digital health,clinical trials,market access,Regulatory,biopharma,Lucid Diligence Brief,payer access,M&A,data platforms,CRO,endpoint technology,eCOAimaging

Lucid Diligence Brief: Thermo Fisher to acquire Clario Professional audiences…

by Timos Papagatsias

Lucid Diligence Brief: Evaxion $7.2m runway extension to H2 2027

November 2, 2025Oncology,Infectious Diseases,clinical trials,Regulatory,biopharma,Lucid Diligence Brief,payer access,capital markets,personalized vaccines,MSD partnership,warrantsSEC filings

Lucid Diligence Brief: Evaxion $7.2m runway extension to H2 2027 Professional…

by Timos Papagatsias

Lucid Diligence Brief: 4DMT APAC License of 4D-150 Gene Therapy to Otsuka

November 1, 2025clinical trials,Regulatory,retinal diseases,biopharma,Lucid Diligence Brief,payer access,diligence,ocular gene therapyAsia–Pacific

Lucid Diligence Brief: 4DMT APAC License of 4D-150 Gene Therapy to Otsuka…

by Timos Papagatsias

Respiratory Video Recap—October 31, 2025

October 31, 2025gsk,pfizer,sanofi,COPD,Asthma,BioPharma and Tech News,Regeneron,Respiratory News,Dupixent,efdoralprin alfaVertex,mNSCLC

This biweekly video recap highlights the most impactful respiratory updates,…

by LucidQuest

Public Health Today—October 31, 2025

October 31, 2025HIV,Alzheimer's Disease,BioPharma and Tech News,spinal cord injury,COVID-19,shingles,Cardiovascular Risk,Public Health News,influenza,Apple,hepatitis Ccannabis,oral anti-amyloid aggregation agents

Explore this week’s public health highlights, including new developments,…

by LucidQuest

Rare Disease Today—October 30, 2025

October 31, 2025novartis,rare diseases,BioPharma and Tech News,Hereditary Angioedema,HAE,Orphan Drug Designation,Avidity Biosciences,Neurofibromatosis Type 1,Rare Disease NewsEU Health Data Space,Myelodysplastic syndromes

Explore this week’s Rare Diseases highlights, including new developments,…

by LucidQuest

Vaccines Video Recap—October 31, 2025

October 31, 2025cytomegalovirus,gsk,pfizer,sanofi,RSV,Moderna,BioNTech,BioPharma and Tech News,melanoma vaccine,COVID-19 vaccine,shingles,Evaxion,Vaccine newsinfluenza,VitriVax

Our biweekly vaccines recap distills the most important developments, from…

by LucidQuest

Vaccines Today—October 31, 2025

October 31, 2025pfizer,sanofi,Moderna,BioPharma and Tech News,melanoma vaccine,RSV Vaccine,COVID-19 vaccineVaccine news,congenital cytomegalovirus

Stay informed with this week’s vaccine updates, highlighting clinical…

by LucidQuest

Respiratory Today—October 31, 2025

October 31, 2025cystic fibrosis,sanofi,BioPharma and Tech News,Respiratory News,AAT deficiency,efdoralprin alfa,Phase 2,VertexWINREVAIR,NACFC

This week’s respiratory news delivers the latest updates, developments, and…

by LucidQuest

Minimize Uncertainty – Make Informed Decisions – Succeed